These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30905222)

  • 1. Long-term evolution of direct healthcare costs for inflammatory bowel diseases: a population-based study (2006-2015).
    Kim JW; Lee CK; Lee JK; Jeong SJ; Oh SJ; Moon JR; Kim HS; Kim HJ
    Scand J Gastroenterol; 2019 Apr; 54(4):419-426. PubMed ID: 30905222
    [No Abstract]   [Full Text] [Related]  

  • 2. Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up.
    van der Valk ME; Mangen MJ; Severs M; van der Have M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; van de Meeberg PC; Mahmmod N; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk C; Vermeijden JR; Siersema PD; Leenders M; Oldenburg B;
    PLoS One; 2016; 11(4):e0142481. PubMed ID: 27099937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease.
    Targownik LE; Benchimol EI; Witt J; Bernstein CN; Singh H; Lix L; Tennakoon A; Zubieta AA; Coward S; Jones J; Kuenzig E; Murthy SK; Nguyen GC; Peña-Sánchez JN; Kaplan G
    Inflamm Bowel Dis; 2019 Sep; 25(10):1718-1728. PubMed ID: 31211836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience.
    Lawton J; Achit H; Pouillon L; Boschetti E; Demore B; Matton T; Tournier C; Prodel M; Peyrin-Biroulet L; Guillemin F
    United European Gastroenterol J; 2019 Aug; 7(7):908-913. PubMed ID: 31428415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Care Cost Analysis in a Population-based Inception Cohort of Inflammatory Bowel Disease Patients in the First Year of Diagnosis.
    Niewiadomski O; Studd C; Hair C; Wilson J; McNeill J; Knight R; Prewett E; Dabkowski P; Dowling D; Alexander S; Allen B; Tacey M; Connell W; Desmond P; Bell S
    J Crohns Colitis; 2015 Nov; 9(11):988-96. PubMed ID: 26129692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
    Kirchgesner J; Lemaitre M; Rudnichi A; Racine A; Zureik M; Carbonnel F; Dray-Spira R
    Aliment Pharmacol Ther; 2017 Jan; 45(1):37-49. PubMed ID: 27781286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation.
    Park KT; Ehrlich OG; Allen JI; Meadows P; Szigethy EM; Henrichsen K; Kim SC; Lawton RC; Murphy SM; Regueiro M; Rubin DT; Engel-Nitz NM; Heller CA
    Inflamm Bowel Dis; 2020 Jan; 26(1):1-10. PubMed ID: 31112238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
    Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
    Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world biologic treatment and associated cost in patients with inflammatory bowel disease.
    Brandes A; Groth A; Gottschalk F; Wilke T; Ratsch BA; Orzechowski HD; Fuchs A; Deiters B; Bokemeyer B
    Z Gastroenterol; 2019 Jul; 57(7):843-851. PubMed ID: 31288280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
    van der Valk ME; Mangen MJ; Leenders M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk CJ; Vermeijden JR; Siersema PD; van Oijen MG; Oldenburg B;
    Gut; 2014 Jan; 63(1):72-9. PubMed ID: 23135759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Direct Healthcare Costs before and after the Diagnosis of Inflammatory Bowel Disease: A Nationwide Population-Based Study.
    Lee J; Im JP; Han K; Kim J; Lee HJ; Chun J; Kim JS
    Gut Liver; 2020 Jan; 14(1):89-99. PubMed ID: 31158951
    [No Abstract]   [Full Text] [Related]  

  • 12. Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in Germany.
    Wilke T; Groth A; Long GH; Tatro AR; Sun D
    Clin Ther; 2020 Jan; 42(1):130-143.e3. PubMed ID: 31883702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Evolution of Health Care Utilisation and Costs for Inflammatory Bowel Disease Over Ten Years.
    Pillai N; Dusheiko M; Maillard MH; Rogler G; Brüngger B; Bähler C; Pittet VEH;
    J Crohns Colitis; 2019 May; 13(6):744-754. PubMed ID: 30916775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct health-care cost utilization in Hong Kong inflammatory bowel disease patients in the initial 2 years following diagnosis.
    Mak LY; Ng SC; Wong IOL; Li MKK; Lo FH; Wong MTL; Leung CM; Tsang SWC; Chan KH; Sze SF; Shan EHS; Lam BCY; Hui AJ; Hung IFN; Leung WK
    J Gastroenterol Hepatol; 2018 Jan; 33(1):141-149. PubMed ID: 28475813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct and Indirect Costs of Inflammatory Bowel Disease: Ten Years of Follow-up in a Danish Population-based Inception Cohort.
    Lo B; Vind I; Vester-Andersen MK; Bendtsen F; Burisch J
    J Crohns Colitis; 2020 Jan; 14(1):53-63. PubMed ID: 31076743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.
    Murthy SK; Begum J; Benchimol EI; Bernstein CN; Kaplan GG; McCurdy JD; Singh H; Targownik L; Taljaard M
    Gut; 2020 Feb; 69(2):274-282. PubMed ID: 31196874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in health-care costs and utilization for inflammatory bowel disease from 2010 to 2014 in Korea: A nationwide population-based study.
    Kim JW; Lee CK; Rhee SY; Oh CH; Shim JJ; Kim HJ
    J Gastroenterol Hepatol; 2018 Apr; 33(4):847-854. PubMed ID: 29055148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
    Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
    Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review.
    Martelli L; Olivera P; Roblin X; Attar A; Peyrin-Biroulet L
    J Gastroenterol; 2017 Jan; 52(1):19-25. PubMed ID: 27665099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Market share and costs of biologic therapies for inflammatory bowel disease in the USA.
    Yu H; MacIsaac D; Wong JJ; Sellers ZM; Wren AA; Bensen R; Kin C; Park KT
    Aliment Pharmacol Ther; 2018 Feb; 47(3):364-370. PubMed ID: 29164650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.